186 related articles for article (PubMed ID: 16387552)
1. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses.
Work LM; Büning H; Hunt E; Nicklin SA; Denby L; Britton N; Leike K; Odenthal M; Drebber U; Hallek M; Baker AH
Mol Ther; 2006 Apr; 13(4):683-93. PubMed ID: 16387552
[TBL] [Abstract][Full Text] [Related]
2. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM
J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615
[TBL] [Abstract][Full Text] [Related]
3. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors.
White SJ; Nicklin SA; Büning H; Brosnan MJ; Leike K; Papadakis ED; Hallek M; Baker AH
Circulation; 2004 Feb; 109(4):513-9. PubMed ID: 14732747
[TBL] [Abstract][Full Text] [Related]
4. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.
Shi W; Bartlett JS
Mol Ther; 2003 Apr; 7(4):515-25. PubMed ID: 12727115
[TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus.
Warrington KH; Gorbatyuk OS; Harrison JK; Opie SR; Zolotukhin S; Muzyczka N
J Virol; 2004 Jun; 78(12):6595-609. PubMed ID: 15163751
[TBL] [Abstract][Full Text] [Related]
6. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
[TBL] [Abstract][Full Text] [Related]
7. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
Shi W; Arnold GS; Bartlett JS
Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
[TBL] [Abstract][Full Text] [Related]
8. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.
Nicklin SA; Buening H; Dishart KL; de Alwis M; Girod A; Hacker U; Thrasher AJ; Ali RR; Hallek M; Baker AH
Mol Ther; 2001 Sep; 4(3):174-81. PubMed ID: 11545607
[TBL] [Abstract][Full Text] [Related]
9. Impact of capsid modifications by selected peptide ligands on recombinant adeno-associated virus serotype 2-mediated gene transduction.
Naumer M; Popa-Wagner R; Kleinschmidt JA
J Gen Virol; 2012 Oct; 93(Pt 10):2131-2141. PubMed ID: 22764318
[TBL] [Abstract][Full Text] [Related]
10. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.
Rabinowitz JE; Bowles DE; Faust SM; Ledford JG; Cunningham SE; Samulski RJ
J Virol; 2004 May; 78(9):4421-32. PubMed ID: 15078923
[TBL] [Abstract][Full Text] [Related]
11. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.
Müller OJ; Kaul F; Weitzman MD; Pasqualini R; Arap W; Kleinschmidt JA; Trepel M
Nat Biotechnol; 2003 Sep; 21(9):1040-6. PubMed ID: 12897791
[TBL] [Abstract][Full Text] [Related]
12. Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.
Hajitou A
Adv Genet; 2010; 69():65-82. PubMed ID: 20807602
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.
Wu P; Xiao W; Conlon T; Hughes J; Agbandje-McKenna M; Ferkol T; Flotte T; Muzyczka N
J Virol; 2000 Sep; 74(18):8635-47. PubMed ID: 10954565
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site.
Huang LY; Patel A; Ng R; Miller EB; Halder S; McKenna R; Asokan A; Agbandje-McKenna M
J Virol; 2016 Jun; 90(11):5219-5230. PubMed ID: 26962225
[TBL] [Abstract][Full Text] [Related]
15. Development of renal-targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p.
Denby L; Work LM; Seggern DJ; Wu E; McVey JH; Nicklin SA; Baker AH
Mol Ther; 2007 Sep; 15(9):1647-54. PubMed ID: 17551506
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.
Siders WM; Shields J; Kaplan J; Lukason M; Woodworth L; Wadsworth S; Scaria A
Hum Gene Ther; 2009 Jan; 20(1):11-20. PubMed ID: 18828728
[TBL] [Abstract][Full Text] [Related]
17. AAV display--homing in on the target.
Lieber A
Nat Biotechnol; 2003 Sep; 21(9):1011-3. PubMed ID: 12949562
[No Abstract] [Full Text] [Related]
18. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.
Favaro P; Finn JD; Siner JI; Wright JF; High KA; Arruda VR
Hum Gene Ther; 2011 Jul; 22(7):843-52. PubMed ID: 21126217
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated viral vectors and their redirection to cell-type specific receptors.
Michelfelder S; Trepel M
Adv Genet; 2009; 67():29-60. PubMed ID: 19914449
[TBL] [Abstract][Full Text] [Related]
20. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries.
Michelfelder S; Kohlschütter J; Skorupa A; Pfennings S; Müller O; Kleinschmidt JA; Trepel M
PLoS One; 2009; 4(4):e5122. PubMed ID: 19357785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
